RedHill Biopharma (RDHL) Change in Accured Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has reported Change in Accured Expenses for 12 consecutive years, with -$3.0 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Change in Accured Expenses fell 38.03% year-over-year to -$3.0 million in Q2 2023; TTM through Jun 2023 was -$12.8 million, a 334.17% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, down 18.51% from the prior year.
• Change in Accured Expenses was -$3.0 million for Q2 2023 at RedHill Biopharma, up from -$7.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $17.8 million in Q2 2020 and troughed at -$7.5 million in Q1 2023.
• A 5-year average of $91111.1 and a median of -$208000.0 in 2019 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 3358.97% in 2019 and jumped 6447.37% in 2020, its largest moves.
• Over 5 years, Change in Accured Expenses stood at -$3.8 million in 2019, then surged by 149.78% to $1.9 million in 2020, then slumped by 83.72% to $309000.0 in 2021, then sank by 1151.78% to -$3.2 million in 2022, then increased by 6.65% to -$3.0 million in 2023.
• The last three Change in Accured Expenses figures came in at -$3.0 million (Q2 2023), -$7.5 million (Q1 2023), and -$3.2 million (Q4 2022), per Business Quant data.